Dyadic raises $2.9 million through stock offering and concurrent warrant placement

Dyadic International, Inc. (NASDAQ: DYAI), doing business as Dyadic Applied BioSolutions, announced on August 13, 2026 definitive agreements with an institutional investor for the purchase and sale of shares of Common Stock in a registered direct offering with a concurrent private placement of warrants to the same investor.¹

The offering price per share of Common Stock was $0.795 and per Warrant was $0.005, with the transactions consisting of the sale of 3,625,000 shares of Common Stock in the registered direct offering and Common Warrants to purchase 3,625,000 shares of Common Stock in the private placement at an exercise price of $0.84 per share.¹ Aggregate gross proceeds to the company from both transactions were expected to be approximately $2.9 million.¹

According to the accompanying prospectus supplement, gross proceeds before expenses will be $2,881,875.00², and the company expects net proceeds of approximately $2,280,143.75 after deducting placement agent fees and estimated offering expenses.²

The transactions were expected to close on or about August 14, 2026, subject to the satisfaction of customary closing conditions.¹ The company said it expects to use the net proceeds, together with its existing cash, cash equivalents, restricted cash and investment grade securities, for general corporate purposes and working capital.¹

Aegis Capital Corp. is acting as exclusive placement agent for the offerings.¹ The registered direct offering is being made under an effective shelf registration statement on Form S-3 (No. 333-273829) declared effective by the SEC on August 25, 2023.¹

The private placement securities are being offered in a transaction not involving a public offering and were not registered under the Securities Act, with sales limited to accredited investors.¹ The company has also agreed to file registration statements covering resale of shares issuable upon exercise of the warrants.¹

Separately, the prospectus supplement noted 36,438,703 shares of common stock outstanding as of August 11, 2026² before the new offering, and disclosed a net tangible book deficit of $(2,387,244), or approximately $(0.07) per share, as of June 30, 2026.²